PharmX Technologies (ASX:PHX) Total Assets: A$18.01 Mil (As of Dec. 2025)


ASX:PHX PharmX Technologies Ltd ASX:PHX
40 GF Score
Price A$0.12
GF Value A$0.07
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is PharmX Technologies Total Assets?

PharmX Technologies ASX:PHX -4.00% 40 Total Assets is A$18.01 Mil as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review.

PharmX Technologies's Total Assets for the quarter that ended in Dec. 2025 was A$18.01 Mil.

During the past 12 months, PharmX Technologies's average Total Assets Growth Rate was 9.70% per year. During the past 3 years, the average Total Assets Growth Rate was -16.30% per year. During the past 5 years, the average Total Assets Growth Rate was -5.40% per year. During the past 10 years, the average Total Assets Growth Rate was 3.40% per year.

During the past 13 years, PharmX Technologies's highest 3-Year average Total Assets Growth Rate was 50.60%. The lowest was -28.30%. And the median was 2.10%.

Total Assets is connected with ROA %. PharmX Technologies's annualized ROA % for the quarter that ended in Dec. 2025 was -5.56%. Total Assets is also linked to Revenue through Asset Turnover. PharmX Technologies's Asset Turnover for the quarter that ended in Dec. 2025 was 0.21.

PharmX Technologies  (ASX:PHX) Total Assets Explanation

Total Assets is connected with ROA %.

PharmX Technologies's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-1.024/( (18.825+18.006)/ 2 )
=-1.024/18.4155
=-5.56 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

PharmX Technologies's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=3.822/( (18.825+18.006)/ 2 )
=3.822/18.4155
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

PharmX Technologies Total Assets Related Terms

PharmX Technologies Total Assets Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies Total Assets Chart

PharmX Technologies Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.35 30.77 36.52 29.86 18.83

PharmX Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.60 29.86 17.97 18.83 18.01
ASX:PHX
40GF Score
PharmX Technologies Ltd ASX:PHX
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmX Technologies Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

PharmX Technologies's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (A: Jun. 2025 )+Total Liabilities (A: Jun. 2025 )
=15.928+2.897
=18.83

PharmX Technologies's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=15.604+2.402
=18.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of A$18.01 Mil mean?
PharmX Technologies (ASX:PHX) has a Total Assets of A$18.01 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on PharmX Technologies and its competitors.
Is PharmX Technologies' Total Assets too high?
PharmX Technologies' current Total Assets is A$18.01 Mil. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' Total Assets compare to VEEV and BTSG?
PharmX Technologies' Total Assets of A$18.01 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Healthcare Providers & Services company?
A good Total Assets depends on the Healthcare Providers & Services industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on PharmX Technologies and its competitors. PharmX Technologies's current Total Assets is A$18.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.12 — trading 71.4% above its estimated fair value. The current Total Assets is A$18.01 Mil. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Total Assets is A$18.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.12 is trading 71.4% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

  • Total Assets: A$18.01 Mil
  • GF Value™: A$0.07 vs. price of A$0.12 (71.4% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score

Get the complete analysis for ASX:PHX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12
Price
A$0.07
GF Value